Patents by Inventor Michael C. Milone

Michael C. Milone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210172020
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 10, 2021
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael C. Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Publication number: 20210087279
    Abstract: Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Application
    Filed: July 28, 2020
    Publication date: March 25, 2021
    Inventors: Boris Engels, Andreas Loew, Michael C. Milone, Li Zhou
  • Publication number: 20210079059
    Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family ?-receptor 4 (GFR?4).
    Type: Application
    Filed: October 23, 2020
    Publication date: March 18, 2021
    Inventors: Donald L. Siegel, Michael C. Milone, Vijay Bhoj, Christoph Rader
  • Publication number: 20210079073
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: April 1, 2020
    Publication date: March 18, 2021
    Inventors: Michael C. Milone, Enxiu Wang
  • Publication number: 20210002377
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: May 27, 2020
    Publication date: January 7, 2021
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Publication number: 20200377589
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: January 15, 2020
    Publication date: December 3, 2020
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • Patent number: 10851149
    Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family ?-receptor 4 (GFR?4).
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: December 1, 2020
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Donald L. Siegel, Michael C. Milone, Vijay Bhoj, Christoph Rader
  • Publication number: 20200371091
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
    Type: Application
    Filed: November 30, 2018
    Publication date: November 26, 2020
    Inventors: Iulian Pruteanu-Malinici, Keith Mansfield, Boris Engels, Jan J. Melenhorst, Adam David Cohen, Edward A. Stadtmauer, Alfred Garfall, Michael C. Milone, Joseph A. Fraietta
  • Publication number: 20200360431
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
    Type: Application
    Filed: November 15, 2018
    Publication date: November 19, 2020
    Inventors: Alfred Garfall, Adam David Cohen, Michael C. Milone, Gabriela Plesa, Edward A. Stadtmauer, Carl H. June
  • Publication number: 20200362012
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 19, 2020
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • Publication number: 20200339651
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 29, 2020
    Inventors: Jennifer Brogdon, Gregory Beatty, David Jonathan Glass, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Huijuan Song, Qilong Wu
  • Publication number: 20200283729
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.
    Type: Application
    Filed: October 11, 2019
    Publication date: September 10, 2020
    Inventors: Andreas Loew, Michael C. Milone, Daniel J. Powell, JR., Yangbing Zhao
  • Patent number: 10738099
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: August 11, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • Publication number: 20200215171
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 9, 2020
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Jonathan Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Patent number: 10577417
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 3, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • Patent number: 10568947
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 25, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Publication number: 20200055948
    Abstract: The invention relates to the treatment of diseases associated with expression of BCMA, in particular myelomas. The invention relates to combination therapies of a BCMA CAR-expressing cell and a gamma secretase inhibitor.
    Type: Application
    Filed: April 27, 2018
    Publication date: February 20, 2020
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Michael Daley, Brian Granda, Michael C. Milone, Selene Guadalupe Nunez Cruz
  • Publication number: 20190375817
    Abstract: The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.
    Type: Application
    Filed: June 4, 2019
    Publication date: December 12, 2019
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Sangwook Oh, Michael C. Milone
  • Publication number: 20190315830
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE
  • Publication number: 20190315831
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE